CleVira is an approved Antiviral formulation for the treatment of various viral infections including viral fever associated with or without thrombocytopenia.
Apex Laboratories Private Limited, a Chennai based pharmaceutical manufacturer and exporter known for Research, Innovation and quality medicines for more than four decades, recently announced the approval of Antiviral drug CleVira as a supporting measure for Mild to Moderate condition of
COVID-19.
Apex Laboratories Private Limited has received approval from Government of India (Ministry of AYUSH) regulators for their Anti-Viral Drug CleVira as an additional indication as a supporting measure for Mild to Moderate condition of COVID-19 making it first of its kind approval in India through various stages of scrutiny at CCRAS (The Central Council for Research in Ayurvedic Sciences) and Inter Disciplinary Technical Review committee (ITRC) a 12 member technical committee constituted by Ministry of AYUSH and headed by Dr SK Maulik Former Professor Department of Pharmacology AIIMS.
CleVira is the brain child of Apex’s R&D Center based on proven scientific evidence and was launched in Indian market aftermath of Dengue outbreak and associated mortality in 2017. CleVira is extensively studied for its safety in animal model (Wistar rats) and efficacy in Human subjects in Phase II and III clinical trials .
CleVira is an approved Antiviral formulation for the treatment of various viral infections including viral fever associated with or without thrombocytopenia. CleVira has proven for its efficacy as Analgesic, Antipyretic and reversal of thrombocytopenia apart from its Antiviral property.